A second Phase III trial of SEL-212
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs SEL 212 (Primary)
- Indications Gout
- Focus Therapeutic Use
- 08 Nov 2019 According to a Selecta Biosciences media release, the U.S. Food and Drug Administration (FDA) has granted Selecta a meeting to be held in January 2020, which is expected to inform the design of the Phase 3 clinical trial.
- 29 Mar 2019 According to a Selecta Biosciences media release, the company plans to initiate this study in the fourth quarter of 2019.
- 27 Aug 2018 New trial record